Finvest
RVTY Life Sciences Tools · Healthcare · Diagnostics · Life sciences · Thesis updated July 12, 2026

Cleaner Revvity, but margins still hurt

01 Running thesis

A cleaner story, not a clean win

Revvity’s latest move is important. Management plans to divest the Immunodiagnostics business in China, which was about 6% of total company revenue last year. That business faced policy pressure and weaker margins, so leaving it should make the remaining company easier to grow.

There is also an early demand signal. In Q1 2026, the core Life Sciences Solutions business returned to positive low-single-digit organic growth. Management said pharma and biotech spending was modestly better, which matters because those customers had been a drag since 2023.

The bear case is still alive because margins are moving the wrong way. In Q1 2026, Life Sciences segment operating margin fell 240 basis points year over year to 28.7%, and Diagnostics fell 100 basis points to 21.8%. A basis point is one hundredth of a percentage point, so these are real moves.

The stock needs proof on three things: the China sale closes, Life Sciences growth lasts more than one quarter, and margins stop sliding. Until then, Revvity looks like a company with a better plan than last year, but not yet a proven turnaround.

May 2026→Q1 2026 confirmed a mixed setup. Revenue improved and the China Immunodiagnostics exit could help the future mix, but margins contracted sharply in both segments.
May 2026▲Management announced plans to divest the China Immunodiagnostics business, which was about 6% of total company revenue last year. That makes the long-term story cleaner if the sale closes.
Feb 2026▼The 2025 10-K showed Life Sciences Solutions declined for the year and margins fell in both segments. It also added goodwill risk, with the Life Sciences Solutions unit close to its impairment threshold.
Nov 2025▼Q3 2025 weakened the recovery case because Life Sciences Solutions slipped back to a revenue decline. Margin contraction also accelerated across both segments.
Aug 2025→Q2 2025 showed Life Sciences Solutions returning to slight growth, a useful sign after weakness. The benefit was offset by another quarter of margin pressure.
May 2025→Revvity changed its segment structure by moving most Applied Genomics into Life Sciences. Life Sciences stabilized, but Diagnostics margins started to compress.
Feb 2025▼Fiscal 2024 results showed Life Sciences revenue declined 3% as pharma and biotech headwinds hurt reagents and instruments. Diagnostics was stronger, but it had to carry more of the thesis.
Nov 2024▲Q3 2024 showed stronger Diagnostics growth and margin expansion, while the Life Sciences decline moderated. That made the story look less one-sidedly negative at the time.
02 Business model

Tools, tests, and repeat use

Revvity makes money by selling instruments, reagents, consumables, software, and services. Instruments are the machines. Reagents and consumables are the items customers use again and again in labs and testing workflows.

The company serves two broad customer groups. Life Sciences sells into research and drug development. Diagnostics sells into clinical testing areas such as immunodiagnostics and reproductive health.

The model works best when Revvity becomes part of a customer’s daily workflow. That can create repeat sales and switching costs. It breaks when customers delay lab spending, when policy changes cut testing demand, or when the company has to sell a lower-margin product mix.

03 Product portfolio

What Revvity sells

Steady

Life Sciences Solutions

This includes reagents, consumables, instruments, and the former Applied Genomics business. It returned to positive low-single-digit organic growth in Q1 2026, but its margin pressure is the main issue to watch.

Option

Software

Software helps labs manage data and workflows. It has been a growth driver, but management has guided for a tough Q2 comparison with software down about 20%.

Cash cow

Immunodiagnostics

This business sells tools and tests used in clinical diagnostics. Revvity is reshaping it by planning to exit the China Immunodiagnostics operation.

Growth engine

Reproductive Health

This is the standout part of Diagnostics. The internal thesis says it continues to grow at a double-digit rate and gives Revvity a high-performing asset.

Option

China Immunodiagnostics

This is the business Revvity plans to sell. The exit should reduce exposure to Chinese diagnostics policy pressure, but the company still needs to close the deal and explain the proceeds.

04 Business segments

Two segments, almost even size

Life Sciences51%modest
Diagnostics49%modest

Segment mix is based on Q1 2026 revenue: Life Sciences revenue was $361.8 million and Diagnostics revenue was $349.3 million. The planned China Immunodiagnostics divestiture will change the Diagnostics mix after it closes.

05 Risk factors

What could go wrong

China divestiture does not close cleanly

High impact · Medium odds

Revvity’s cleaner story depends on selling the China Immunodiagnostics business. The company has warned that failure to execute divestitures could create unexpected costs and disrupt operations. If proceeds are weak or the sale takes longer than expected, the strategic benefit could shrink.

We watchDeal closing, disclosed sale proceeds, stranded costs, and management’s capital redeployment plan.

Margins stay under pressure

High impact · High odds

Q1 2026 showed revenue growth, but not profit improvement. Life Sciences segment operating margin fell 240 basis points year over year, while Diagnostics fell 100 basis points. If product mix, tariffs, currency, and investment spending keep hurting margins, revenue growth may not turn into better earnings.

We watchLife Sciences margin versus 28.7% and Diagnostics margin versus 21.8% in upcoming quarters.

Life Sciences recovery fades

High impact · Medium odds

The bull case needs more than one good quarter. Life Sciences Solutions had declined in fiscal 2025, then returned to low-single-digit organic growth in Q1 2026. If pharma and biotech customers slow orders again, the recovery thesis weakens fast.

We watchOrganic growth in Life Sciences Solutions and management comments on pharma and biotech spending.

Goodwill impairment in Life Sciences Solutions

Medium impact · Medium odds

The 2025 10-K said the Life Sciences Solutions reporting unit had $4.5 billion of goodwill. Its fair value exceeded carrying value by only more than 10% but less than 20% at the November 3, 2025 test. Continued weak margins or demand could lead to a material impairment charge.

We watchAny interim impairment update, lower Life Sciences forecasts, or a new goodwill charge.

Software growth proves lumpy

Medium impact · Medium odds

Software has helped offset weakness in other Life Sciences products. But the internal thesis says the software business faces tough Q2 comparisons and is guided to be down about 20%. That makes it harder to treat software as a smooth near-term growth engine.

We watchQ2 software revenue growth, renewal timing, and new order commentary.
06 Quick answers

In one breath

What does Revvity do?

Revvity sells tools used in health science research and clinical testing. Its products include instruments, reagents, consumables, software, diagnostics tools, and services.

Why is Revvity selling its China Immunodiagnostics business?

Management said the business was about 6% of total company revenue last year. The goal is to reduce exposure to policy pressure in China and focus capital on higher-return areas.

Is Revvity growing again?

Partly. Q1 2026 revenue rose in both segments, and Life Sciences Solutions returned to low-single-digit organic growth. The key question is whether that growth lasts while margins recover.

What is the biggest risk for Revvity stock?

The biggest watch item is margin pressure. If Life Sciences and Diagnostics keep losing margin even as revenue rises, earnings power may disappoint.